



Relato de caso

Utilidade de bioquímica post-mortem em patologia forense: relatos de casos ilustrativos

Cristian Palmiere, Maria del Mar Lesta, Sara Sabatasso, Patrice Mangin, Marc Augsburger, Frank Sporkert

University Center of Legal Medicine, Lausanne, Geneva, Rue du Bugnon 21, 1011 Lausanne, Switzerland Rue Michel-Servet 1, 1211 Genève 4, Sua

ARTICLE INFO

Article history:

Recebeu 6 de setembro de 2011

Recebido, em forma de revista, 25 de outubro de 2011

Aceito 26 de outubro de 2011

Disponível on-line 15 de dezembro de 2011

Palavras-chave:

Bioquímica post-mortem

Causa da morte

Processo de morte

Patologia Forense

E S O

O objetivo deste trabalho é apresentar algumas aplicações de bioquímica post-mortem, práticas para ilustrar a utilidade desta disciplina e reafirmar a importância da realização de investigações bioquímicas como parte integrante do processo de autópsia. Cinco relatos de casos são apresentados relativos a cetoácidos e diabetes.

Um adulto que não era conhecido por sofrer de diabetes em presença de vários psicotrópicos sub-positivos; e a injeção fatal de intoxicação em um Metabolizador por também apresentar um insuficiência renal;

cetoácidos diabéticos mostrados graves alterações post-mortem; aldosteronismo primário, apresentado com intracranial hemorragia e hipotermia mostrados graves alterações post-mortem. Os casos aqui apresentados podem ser considerados representativos de casos de importância para a investigação bioquímica post-mortem.

Esses, que podem fornecer importantes informações para determinar a causa de morte em casos forenses rotineiros ou contribuir para a compreensão dos mecanismos fisiopatológicos envolvidos no processo de morte.

© 2011 Elsevier Ireland Ltd. Todos os direitos reservados.

1. Introdução

Um dos primeiros informes sobre bioquímica forense foi publicado em 1940 e pertencia a maglósios no sangue após a morte

determinação [1]. Em este estudo (*Postmortem glycolysis*), Hamilton-Paterson e Johnson [2] realizou uma investigação de casos de fty, incluindo oito indivíduos com diabetes, sete dos quais

com coma, e medido o glicose concentrações em diferentes substratos, incluindo sangue coletado de diferentes sites de amostragem (aurícula direita, artéria pulmonar e aorta), cérebro-espinhal e amostras de fígado. Os resultados destas investigações indicaram que a glicólise que tinha ocorrido de sangue dos vasos periféricos, enquanto os valores de glicose foram maiores no sangue cardíaco

de aurícula direita devido a glicogenólise hepática. Além disso, as concentrações de glicose foram maiores no sangue das extremidades em dimetro - Bética indivíduos, na qual a glicólise pós-morte também ocorreu mais lentamente do que o habitual. Dezenove anos mais tarde, Naumann [3] publico o primeiro relatório sobre os constituintes químicos de vitreos humanos

(*Postmortem chemistry on the vitreous body in man*), sobre qual conhecimento foi previamente limitado para decidir de análise de olho humano sem necropsia. Este estudo foi conduzido em 211 cadáveres humanos e teve como objetivo comparar o post-mortem química de esqueleto sangue, vitreos e humanos e utilizados para a química antes da morte de vid espinal e sangue venoso. Os parâmetros analisados incluem glicose,

nitrogênio de uréia, creatinina e eletrólitos, como potássio sódio, e

Sucedendo Naumann, numerosos pesquisadores mostraram interesse em bioquímica após a morte, e muitos estudos sobre este tema apareceram em revistas médico-legais, nomeadamente concerning de sangue e vítreo de compostos químicos e o postmortem...

tem diagnóstico de distúrbios do metabolismo de glicose e distúrbios eletrolíticos. Um grande número de estudos relativos ao vitreos glicose e eletrólitos, hemoglobina glicosilada e proteínas do sangue e hormônios, bem como compostos de nitrogênio em vários fluidos biológicos tm sido levados para fora ao longo deste período e contribuíram para reforçar o papel da bioquímica após a morte como uma ferramenta de diagnóstico promissora e significativa para oferecer suporte a patologia forense rou-dentes [4-21].

Em 1993, Coe [22] publico um artigo de direito *Apsa morte Chemistry Update: Emphasis on Forensic Application*, em que ele revista bioquímica post-mortem e artigos referentes a este assunto sobre o último 15 anos. Em sua introdução, Coe definiu bioquímica forense como um dos auxiliares mais importantes no diagnóstico para o patologista forense em fase de importância análise sistemática de vitreos, eletrólitos, glicose e uréia e nitrogênio como métodos que podem fornecer importantes informações para determinar a causa da morte e resolver problemas forenses

SIC em muitos casos de natural morte. A seguir Coe, numerosos pesquisadores em aproximadamente Bioquímica realizados estudos dirigidos a marcadores bioquímicos clínicos e com o objetivo de verificar a possibilidade de incluir métodos bioquímicos na análise utilizada na prática clínica em forense patológica. A investigação de Porisso, o número de substâncias que so

Autor correspondente. Tel.: + 41 021 314 49 61; Fax: + 41 021 341 70 90.

E-mail address: Cristian.Palmiere@chuv.ch (C. Palmiere).

potencialmente til para fins de diagnóstico nas rotinas de patologia forense tem significativamente aumentada. Vrias publicaes tm marcadores ad-vestida de abuso delcoole ingestode lcool, marcadores bioquímicos da funo cardíaca e isquemia miocrdica, inamma-o, infeco e sepse, bem como anafilaxia, anemia ou hipóxia após a hemorragia, leses cerebrais, doenas hormonais e distrbios hormonais, quetambempodemserdetectadosem muitas situaes-es

que forense patologistas Atualmenteconfronta(porexemplo, morte, asfixia e hipotermia). Apósamorte determina-es de uma grande variedade de moléculas agora so tecnicamente possíveis na maioria dos uids biológicos, incluindo sangue, humor vítreo, urina e uids uidos, pericrdico e sinovial [23-32]. Apesar do inegvel progresso alcanado ao longo das ltimas décadas em termos de moléculasquepodemserdetectadasem médico-legaissituaesquepodem ser elu-cidated em bioquímica post-mortem, investigaes bioquímicas post-mortemsoaindaincorpo-em

Pontuao: o rotinasde de forense patologistas. Em unrelatório Publicado por Luna [33] em 2009, intitulado *Postmortem chemistry really useful? Why it is not widely used in forensic pathology?*, o autorressaltouofatodequeapósamortebioquímicosmetanfetamina-odsaindatmpoucainformaen as rotinas de Patologia Forense por causa deumasériedeproblemas, incluindo dificuldades na interpretao dos resultados de tais anlises, a ausncia de bancos de dados com meros de suficiente decaos para estabelecer as faixas normais de autópsias médico-legais, insuficiente conhecimento sobre diagnóstico potencial de bioquímica após morte e a ausncia de publicaes que estabelecem uma correspondncia confiável entre decídios histopatológicos e os resultados das investigaes bioquímicas post-mortem. autor

O concluiu que após morte bioquímicos métodos de deve ser integrada na rotina da autópsia com precauo em contaparmetros de ing para quais dados so incompletos ou convincentes, mas com nfiana em situaes onde os dados so conclusivos e onde h provas de suficiente, tais como para glicose vítreo e marcadores bioquímicos do miocrdio em uid pericrdica.

Na Universidade de direito de jurídic medicina Lausanne-Genebra, métodos de bioquímica post-mortem, tomografia computadorizada (CT), CT-angiografia, histologia, e Toxicologia so realizada de rotina com parte integrante da autópsia forense processo. Anlise sistemática de vítreo glicose, sódio, cloreto, uréia, nitrogênio e creatinina, glicosilada hemoglobina, sangue 3-β-hidroxibutirato, acetona e lcool isopropílico, bem como proteína C-reativa, pró-calcitonina, interleucina-6, triglicérides, Costa-

Terol, proteínas totais, albumina, bilirrubina total e troponina I em post-mortem soros de sangue femoral so realizadas em todos os casos de mortes bita. Vítreo urina 3-

β-hidroxibutirato, acetona e lcool isopropílico determina-es constam estas análises em casos selecionados. Com base nas nossas investigaes realizadas em mais de 800 cadáveres admitidos ao nosso centro desde 2008, nossa é

opinio que métodos bioquímicos pós morte representam um procedimento adicional importante para os patologistas forenses em investigar as causas e processos envolvidos na morte, bem como as condies de con-tribuindo de canais e predispondo a doenas. O objetivo deste trabalho é apresentar algumas prticas de bioquímica post-mortem aplicadas para ilustrar a utilidade desta disciplina e para afirmar

a importncia da realizao de investigaes bioquímicas como parte integrante do processo de autópsia.

2. case 1

2.1. Unexpected fatal diabetic ketoacidosis

Mortes bita após o início agudo de um coma diabético é real-mente rara. Diabetes apresenta-se geralmente com os sintomas clássicos de polidipsia, poliúria, polyfagia e perda de peso, mas em algumas situa-ções, diabetes notratada podem se manifestar com um coma diabético [34].

Anlises química pós-morte podem facilmente identificar casos de cetoacidose diabética fatal com base na existncia de valores elevados de glicose no vítreo (e uids uidos) acompanhado de cetonas corporais aumentadas em vrios substratos, incluindo sangue e humor vítreo [22,29-32,35-40]. Um nmero de relatórios foram publicados sobre o diagnóstico post-mortem de insuspeita cetoacidose diabética em adultos e crianas [22,34,41-45]. Além disso, hrias

estudos publicados endeream a diabético cetoacidose como um possível fator complicador em mortes associadas com drogas acabou-doses [46-49].

O caso aqui apresentado preocupa-se um homem de 37 anos de idade (r.), encontrado morto em uma noite de sexta-feira às 21:00 no apartamento de um amigo (b), onde ele estava hospedado desde que voltou para a terra de Suíça. B. revelou que ambos os indivíduos tinham consumido cocaína por fumaria no dia anterior. No dia da morte, r. ficado na cama adormecido, estava extremamente cansado e vomitou vrias vezes, enquanto B. nosofria qual quer problema físico.

. tinha vivido na Suíça até 5 anos antes de sua morte, quando ele decidiu voltar para o Reino Unido, onde foi originalmente

De. Por conseguinte, o centro médico informa-es foi No disponível para este indivíduo. O clínico geral que foi lowered r. Suía informou que o paciente sofria de hepatite B e C, lcool, maconha e heroína vício e psy-chosis com a mania bipolar, para o qual ele tinha dado mirtazapina. Ele também recebeu 50 mg de metadona todos os dias durante um período de 2 anos antes de deixar a Suíça. O médico confirmou que seu ltimo exame deste paciente havia sido conduzido 5 anos anteriormente e que desde o exame no tinha tido qual quer notícia de seu paciente.

Informaes médicas obtidas a partir de servios locais de sade - portados esses fatos. R. foi admitido ao hospital após pequeno trauma sem duas instncias diferentes, durante o qual ele relacionado como consumo de cannabisol e de medicamentos sem base regular e persistiu - tencede consumo de heroína, apósdotratamentocom metadona. Médica infor-mao sob seus ltimos 5 anos passados no Reino Unido no estava disponível. No entanto, os pais relataram que nosofria de algum doena específica.

Quando ele foi encontrado morto, seu corpo estava deitado em uma cama, e a visom macroscópica externa do corpo na cadáver revelou a sem fermentos. O falecido tinha 177 cm de altura e pesava 62 kg. Radiologia e exame externo no revelou a fízi-ramalgonotvel. Seu corao pesava 350 g e mostrou algumas hemorragias petequiais sob pericrdio, bem como um menor hipertrofia ventricular esquerda (espessura média, 1,6 cm). Em geral, o miocrdio exibia mltiplas isquias, e as artérias coronárias no apresentavam morfologias anormais dos italianos. Ambos os pulmões estavam congestionados (esquerda, 700 g; direito, 670 g). O fgado pesou 2170 g e apareceu um marrom amarelado, mas nenhum nódulo nodular foram encontrados. Abexigaurinria contido 1020 ml de urina. outros

órgos, incluindo o cérebro (peso, g de 1510 g) ao (140 g) rins (direito, 190 g; esquerda, 190 g), mostramos signifi-cant alteraes patológicas. Os exames histológicos revelaram um grau de hipertrofia miocrdica, inltrates linfocíticos na veia

Portal regies, hepática esteatose hepática, aguda renal tbulonecrose e hialinizados glomérulos nos rins, aguda congesto visceral e edema cerebral e pulmonar.

Realizaram-se análises toxicológicas em amostras de sangue, urina e cabelo colhidas na autópsia e sangue incluído seta no ldetermi-nao e rastreamento de drogas com uso de substncias ilegais por

gromatografia de massa espectrometria (GC-MS), alta-performance cromatografia líquida com díodos (HPLC - DAD), deteco de ionizao do gs headspace cromatografia a me (HS-GC-FID) e cromatografia líquida acoplada a espectrometria de massa em tandem (LC-MS/MS). Os resultados so mostrados na tabela 1.

As concentraes nos sangue do sujeito de buprenorfina, #Pages [3] norbuprenorphine, nordiazepam e oxazepam estavam dentro da teraputica

Table 1

Caso 1: Resultados das análises toxicológicas realizada no sangue, urina e cabelo.

Substância	Sangue	Urina	Cabelo
Mirtazapina e metabólitos	Traos	Traos	N.e.
Morfina livre	<5 µg/l	85 µg/l	0,45 ng/mg
Morfina-3-glicuronídeo	54 µg/l	N.d.	N.e.
Morfina-6-glicuronídeo	<5 µg/l	N.d.	N.e.
Morfina total	38 µg/l	1000 µg/l	N.e.
Cocaína	N.d.	12 µg/l	21 ng/mg
Benzoilecgonina	N.d.	250 µg/l	3,7 ng/mg
Methylecgonine	N.d.	88 µg/l	N.e.
Buprenorfina	1,0 µg/l	73 µg/l	N.e.
Norbuprenorphine	1,0 µg/l	36 µg/l	N.e.
Nordiazepam	124 µg/l	N.d.	N.e.
Oxazepam	<5 µg/l	N.d.	N.e.
Metadona	N.d.	N.d.	5,6 ng/mg
EDDP	N.d.	N.d.	0,7 ng/mg
6-Monoacetylmorphine	N.d.	N.d.	2,8 ng/mg
Codeína livre	N.d.	N.d.	0,13 ng/mg
Codeína total	N.d.	N.d.	N.e.
Icoetilíco	N.d.	N.d.	N.e.

N.d. = no detectado.

N.e. = no avaliada.

intervalos. A presença de Mirtazapina e seus metabólitos no nível baixo no sangue e urina indicou uso recente desta substância, provavelmente remonta a várias horas ou mesmo dias antes da morte. As concentrações de sangue e urina de morfina e seus glucuronídeos indicaram um uso no recente de heroína ou morfina. Finalmente, a presença de cocaína e seus metabólitos na urina e seu Aguiar-sencen no sangue indicam uso no recente desta substância,

provavelmente remonta a várias horas antes da morte, que era consistente com o período de amigra. A morfina de concentrações de cocaína, benzoilecgonina, metadona, EDDP, 6-monoacetylmorphine e codeína no cabelo do sujeito indicado cocaína, heroína e metadona usam regularmente durante os meses anteriores a sua morte.

Neste momento a investigação, a causada morte foi claramente estabelecida. Naverdade, as concentrações das diferentes substâncias secundárias encontradas no sangue do sujeito não podem explicar sua morte, especialmente quando considerado individualmente. Consequentemente, porque os resultados das análises toxicológicas realizadas neste caso são essenciais para o diagnóstico principal e a ausência de evidências macroscópicas e microscópicas um importante papel em causar a morte pode ser atribuído para as substâncias farmacológicas depressoras

e efeitos exercida por diferentes psicotrópicos substâncias no sistema nervoso central, mesmo que as suas concentrações eram relativamente baixas. Não podemos descartar a possibilidade de que em uma situação semelhante com resultados inconclusivos após a autópsia, análises de histologia e toxicologia e onde não tem post-mortem foram realizadas análises bioquímicas, teri provavelmente concluímos que a causada morte foi claramente estabelecida mas que os efeitos adversos dos usos simultâneos de múltiplas

substâncias psicotrópicas poderiam ter desempenhado um papel contribuindo em causar a morte.

No entanto, como as análises no humor vítreo são sistematicamente por - formada em nosso centro de médico-legais, e valores de álcool acetona e isopro-pyl no sangue são rotineiramente determinados durante a análise de etanol por HS-GC-FID, aumentada foram detectadas concentrações de glu-cose de cetona e vítreo de sangue. Por conseguinte, outras análises de bioquímica foram realizadas em vários substratos e confirmada a existência de hiperglicemia e cetose no momento da morte. Resultados de investigações bioquímicas são mostrados na tabela 2. Com base nestes resultados, que sugeriu a cetose diabética grave como a causa da morte, foram realizadas análises histológicas das ilhotas de Langerhans, o glucagon normal imunoreatividade e quase ausência de imunoreatividade de insulina.

Finalmente, com base em todas estas decisões, concluiu-se que a causada morte foi uma grave cetose diabética em um assunto que não era conhecido por sofrer de diabetes.

O caso neste documento pode ser considerado um ilustrativo exemplo da importância de exames sistêmicos em ordem para diagnosticar a causa de morte em casos de autópsia. Investigações post-mortem de bio-química devem ser regularmente realizadas, em vários substratos, se necessário, além de toxicologia em indivíduos com histórias ou provas locais de diabetes e uso de drogas possíveis. Além destas devem ser realizadas quando os resultados da investigação preliminar não produziram uma interpretação conclusiva.

3. Case 2

3.1. Fatal intoxication in a poor metabolizer exhibiting impaired renal function

Níveis de sódio vítreo foram determinados para ser relativamente estáveis durante o período post-mortem e apresentar concentrações semelhantes às encontradas nos outros indivíduos vivos (135-145 mmol/l) [1,3,6,7,12]. De acordo com Coe [22], anormalidades nas concentrações de sódio no soro antes da morte reedem valores vitreos pós-morte, tornando possível diagnosticar hiponatremia no momento da morte. Comportamento pós-mortem de cloreto no soro é considerado semelhante ao de sódio, com apenas um mínimo de diminuição observada durante o início após a morte

período, e com concentrações semelhantes às encontradas no soro de indivíduos vivos (105-132 mmol/l) [3,6,7]. Tal como acontece com o sódio, anormalidades no soro antes da morte, concentrações de sódio reedem valores vitreos pós-morte, tornando possível diagnosticar distúrbios de eletrólitos no momento da morte [22]. A zotoureicofoim mostrada para ser um composto muito complexo, com após a morte no soro níveis de eletrólitos aproximando-se antes da morte os valores, independentemente da metodologia utilizada e as concentrações, mesmo depois de moderada decomposição do corpo. Estudos realizados em indivíduos revelaram um aumento insignificante na uréia e nitrogênio no soro após a morte, como níveis de eletrólitos reedem concentrações pós-morte. As mesmas conclusões foram relatadas para o vítreo e mesmo no líquido. Semelhante ao zotoureico, níveis de creatinina no soro são considerados permanentemente elevados em vários tipos de morte, incluindo o vítreo. Além disso, por falta de estimar a função renal, aumentos de nitrogênio uréico são associados com hiperpotassemia e podem contribuir para a morte de desidratação, que geralmente provoca uréia e níveis de nitrogênio subnormais e níveis de creatinina

do que [18,225]. Coe [22] Primeiramente creveu quatro características eletrolíticas desreguladas no soro e vítreo, incluindo o padrão de desidratação, que é tipicamente caracterizada por aumento das concentrações de sódio e cloreto associado com pequenos aumentos na uréia. Madea e Lachenmeier [50] valores de cloreto enfatizada podem elevar de sódio vítreo e também encontrados relacionados às causas de morte além de desidratação e que conclusões sobre a causada morte geralmente devem ser baseadas em um assunto completa morfológica e toxicológica status, ser-causa bioquímica vítreo e zinhanopermite qualquer conclusão sobre resultados encontrados.

Diagnóstico de desidratação e pré-renal falha confirmada por avaliação da função renal pode ser extremamente útil em forense. SIC-rotinas de toxicologia, tais como em casos de intoxicação com drogas que são parcialmente ou totalmente eliminadas pelos rins porque aumentar grandemente as concentrações no sangue, dependendo do acumulado resultante de insuficiência renal. Além disso, raras situações podem ocorrer em que o metabolismo de um composto eliminado pelos rins é também marcadamente reduzido por causa de um defeito genético relativo, por exemplo, um Escherichia citocromo. Nestas circunstâncias, a presença de acúmulo

Table 2

Case 1: Results of postmortem biochemistry analyses, which revealed high glucose levels in vitreous and cerebrospinal fluids as well as high acetone and 3-hydroxybutyrate concentrations in several substrates.

Analyte	Blood	Vitreous humor	Cerebrospinal fluid	Urine	Pericardial fluid	Liver
Acetone	500 mg/l	630 mg/l		1200 mg/l		
Acetoacetate	<20 µmol/l	1949 µmol/l	118 µmol/l	2297 µmol/l	<20 µmol/l	59 µmol/l
3-β-Hydroxybutyrate	13,910 µmol/l	15,263 µmol/l	10,997 µmol/l	62,102 µmol/l	15,307 µmol/l	13,600 µmol/l
Isopropyl alcohol	43 mg/l	40 mg/l		43 mg/l		
Glycated hemoglobin	11.4%					
Glucose		36 mmol/l	36 mmol/l	162 mmol/l		
Urea nitrogen		21 mmol/l				
Creatinine		80 µmol/l				
Sodium		135 mmol/l				
Chloride		107 mmol/l				
C-reactive protein	53 mg/l					
Procalcitonin	<0.25 µg/l					
Triglycerides	12 mmol/l					
Cholesterol	11.3 mmol/l					
Troponine I	0.24 µg/l					
Tryptase	6.27 µg/l					

Empty boxes: parameter not evaluated.

blood of pharmacologically active molecules (caused by the metabolic defect) may be aggravated by the deficiency of renal activity. We observed the case of a 69-year-old man weighing 69 kg and

suffering from mild cognitive decline, who was found dead at home by his wife. In the past, he had suffered from paroxysmal supraventricular tachycardia, for which he was medically treated with flecainide (100 mg/day) for a short period. His blood flecainide concentrations were not checked at the time of the treatment, which was stopped 3 years previously and reintroduced some weeks prior to his death. Other anamnesticly important information concerned two hospitalizations following dehydration due to diarrhea and insufficient water intake.

Radiology, external and internal examination did not reveal anything remarkable except for dry skin. The subject's heart weighed 350 g, and his coronary arteries exhibited mild atherosclerotic disease. Histological examination of the heart did not indicate any particularities. Toxicological analyses were performed on the blood and urine samples (a small quantity) collected during the autopsy and included blood ethanol determination and screening for common drugs and illegal substances by GC-MS, HPLC-DAD and HS-GC-FID. Gastric contents were absent. The analyses revealed

the presence of parent flecainide in the blood (6100 µg/l) and urine (54,000 µg/l) but insignificant meta-O-dealkylated flecainide concentrations in both fluids. Determination of flecainide was not performed in bile, vitreous, liver or kidney. Based on these data, i.e., toxic concentrations of flecainide and virtually no meta-O-dealkylated flecainide, metabolic disturbance was indicated and was confirmed by CYP2D6 genotyping, which revealed a homozygous PM/PM

CYP2D6 genotype (poor metabolizer). Finally, biochemical analyses revealed increased vitreous sodium and urea nitrogen values (148 mmol/l and 62 mmol/l respectively), a less significant increase

in the creatinine concentration (160 µmol/l) and a low glucose level (0.8 mmol/l). Biochemical analyses carried out in the urine showed a reduced sodium concentration (25 mmol/l). All of these results indicated a depressed glomerular filtration rate and a prerenal failure, which could also have contributed to reducing the elimination of flecainide from the body. The cause of death was determined to be flecainide intoxication in a CYP2D6 poor metabolizer exhibiting impaired renal function, which cooperated in causing an increased flecainide concentration in the blood finally leading to the death.

Compared to the first case that we have described, this second case emphasizes both the importance of pharmacogenomics as an adjunct in the interpretation of toxicological results and the

diagnostic potential of forensic biochemistry, which again provided significant information in elucidating toxicological findings.

CYP2D6 genotyping has frequently been employed as a supplementary tool in the determination of drug toxicity and the interpretation of forensic toxicological results [51–58].

A great number of correlations between parent drugs with metabolites, which are related to polymorphisms in CYP enzymes, have been reported for opioids (oxycodone, tramadol, methadone, fentanyl and codeine) [59–64], psychotropic drugs (fluoxetine, paroxetine, citalopram, doxepine and amitriptyline) [65–70] and cardiovascular drugs, including antiarrhythmic agents [71–79]. Most of these compounds are associated with hepatic metabolism and very

few substances are eliminated almost exclusively by the kidneys.

Several cases of fatal flecainide intoxication have been reported in the clinical and forensic literature [80–91]. Flecainide plasma concentrations in patients with renal failure have been investigated by several authors. Results of these studies have confirmed that extreme caution must be observed when treating with flecainide patients with impaired renal function. Moreover, some re-

ports suggested that renal clearance is the major route of flecainide elimination in the subpopulation of CYP2D6 poor metabolizers [92–97].

These situations are relatively infrequent. However, the case herein reported emphasizes the importance of systematic examinations in order to diagnose the cause of death in autopsy cases, particularly when pharmacogenomics, toxicology and biochemistry, individually or combined, may contribute to understanding the pathophysiological mechanisms involved in the death process.

4. Case 3

4.1. Hypothermia (also presenting postmortem changes)

Biochemical changes have been described in fatal hypothermia cases [98–101]. Most of these changes pertain to the secretion of hormones, with the aim of increasing the heat production. Ishikawa et al. [102–105] and Yoshida et al. [106] investigated the adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), catecholamine and chromogranin A levels in postmortem serum from cardiac blood and cerebrospinal fluid and compared the results with immunohistochemical

analyses in the hypothalamus, adenohypophysis and adrenal medulla. Quan et al. [107] investigated

serotonin levels in cerebrospinal and pericardial fluids. According to the results of these investigations, which showed decreased hormone levels in the blood in hypothermia cases, these authors postulated that in a cold environment, TSH and ACTH production could initially increase to generate heat and subsequently be suppressed by metabolic disorders involving abnormal lipid metabolism in advanced hypothermia [102–104]. Similarly, the results of these studies indicated

ies systemic and progressive deterioration of the sympathetic/adrenomedullary system due to fatal cold exposure, a terminal state of hypothalamus dysfunction and systemic neuronal dysfunction in prolonged death due to cold exposure, implying disturbances in blood catecholamine and chromogranin A levels as well as in cerebrospinal fluid serotonin levels [105–107]. Teresiński et al. [108–110] investigated ketones as biochemical markers of hypothermia and the usefulness of determining ketones in the blood, urine and vitreous humor in diagnosing death by hypothermia. These authors started from the assumption that cases of hypo-

thermia are usually accompanied by ketonemia and ketonuria, which are easily detectable using routine diagnostic procedures as a result of a decrease in the concentration of glucose in the blood associated with enhanced release of counterregulatory hormones. This intensifies the metabolism of fats and the production of ketones, which constitute the main sources of energy after the glycogen reserve

gen has been used, that is necessary to increase heat production in a cooled organism. Moreover, as the consumption of large amounts of ethanol modifies the cellular redox balance and exerts an inhibitory effect on ketone production by hepatocytes, a clear inverse relation between blood ketone levels and the severity of insobriety has been observed in hypothermia cases. Systematic ACTH, TSH and catecholamine measurements in blood are not routinely performed in hypothermia cases, even when they should be, in part due to the special preanalytical procedures required. However, acetone and 3-

β -hydroxybutyrate in the blood as well as in other substrates, including urine and vitreous, are easily detectable using routine diagnostic procedures and should be systematically measured in all suspected hypothermia cases, even (or especially) when bodies show advanced postmortem changes and only small amounts of blood may be obtained during the autopsy.

We observed the case of a 45-year-old man found dead in February in a wooded area almost totally covered by snow presenting advanced postmortem changes as well as large and diffuse wounds caused by postmortem animal predation. Radiological investigation prior to autopsy only revealed internal decomposition changes. External examination did not allow any appreciation of frostery-

thema or lividity but revealed severe postmortem changes and animal predation, notably of the face and the right lower limb. During the internal examination, Wischniewski spots and hemorrhages in the right psoas muscle were observed. The pancreas showed marked autolytic changes. Toxicological analyses were performed on blood and urine samples collected during the autopsy and included blood

ethanol determination and screening for common drugs and illegal substances by GC-MS, HPLC-DAD and HS-GC-FID. Vitreous and cerebrospinal fluid were absent. No ethanol was detected in the blood, whereas oxazepam, nordiazepam, and lorazepam were found in both fluids within the therapeutic ranges. Biochemical analyses were performed on the blood and urine and allowed identification of acetone, 3-

β -hydroxybutyrate (3HB) and isopropyl alcohol (IPA) in both substrates: β -hydroxybutyrate: 6700 and 24,390 $\mu\text{mol/l}$ in the blood and urine, respectively; acetone: 83 mg/l in the blood; isopropyl alcohol: 12 mg/l in the blood, as well as a normal level of glycated hemoglobin.

On the basis of all four analyses, we concluded that hypothermia was the cause of death and that the benzodiazepines detected

in the toxicological analyses could have played a role in the death process, probably reducing the subject's ability to respond to cold exposure. These conclusions were supported by both the autopsy

findings and biochemical results, which were able to be carried out and provided useful data, even with very small amounts of biological fluids.

The case here presented can be considered representative example not only of the usefulness of postmortem biochemistry investigations in helping to determine the cause of death, but also of the importance of performing these analyses even in the presence of small amounts of biological material.

5. Case 4

5.1. Diabetic ketoacidosis and severe postmortem changes

Severe postmortem changes can also significantly limit the possibilities of diagnosing metabolic disorders, such as diabetic ketoacidosis [111]. In severely decomposed bodies, vitreous, urine, blood, postmortem serum and cerebrospinal and pericardial fluids are absent in most cases, and biochemical analyses are difficult to perform. Moreover, several volatile organic compounds are produced during different stages of human decomposition, including alcohols and ketones, making interpretation of biochemistry results particularly problematic [112–113]. Within the limits of the small amount of material that can be obtained during the autopsy and bearing in mind that the results of biochemical investigations must be interpreted very cautiously, samples for 3HB determination including blood and tissue samples should be always obtained and such analyses should be systematically carried out in all cases of sudden death, particularly in individuals with histories of evidence at the scene indicating diabetes mellitus, hypothermia or alcohol misuse-related deaths. We investigated the case of a 29-year-old insulin-dependent diabetic man, found dead at home in a state of advanced decomposition, characterized by brown discoloration, marbling of the chest and upper extremities, skin slippage and purging of a dark brown fluid. The radiological investigation prior to autopsy only revealed the presence of large amounts of putrefaction-generated gases in most organs and vessels. The subject's internal organs exhibited moderate to advanced decomposition changes. Only 2 ml of cardiac blood and samples of certain tissues (liver, kidney and skeletal muscle) were recovered for tox-

ological which included ethanol determination and screening for common drugs and illegal substances by GC-MS, HPLC-DAD and HS-GC-FID. Determination of 3HB was performed in peripheral blood stored in a tube containing sodium fluoride and deproteinized with the same amount of perchloric acid as well as in liver and kidney homogenates obtained from liver and kidney samples treated with sodium chloride and deproteinized with the same amount of perchloric acid. The 3HB concentration was determined

using an enzymatic photometric method. Blood analyses revealed the presence of ethanol (0.86 g/l, corresponding to 0.18 mmol/l), acetone (30 mg/l, corresponding to 518 $\mu\text{mol/l}$) and 3HB (9600 $\mu\text{mol/l}$), as well as traces of other volatile organic compounds. Analyses of liver and kidney samples revealed 3HB concentrations of 11,550 and 10,350 $\mu\text{mol/l}$. In a series of 10 non-diabetic, severely decomposed bodies, determination of blood, liver and kidney 3HB, carried out in the same amounts of blood and tissue homogenates and with the same analytical techniques, always revealed 3HB concentrations within the normal range, never exceeding 200

$\mu\text{mol/l}$. On the basis of these analyses, we cautiously concluded that the observed 3HB concentrations could be elements supporting the hypothesis of diabetic ketoacidosis as the cause of death in an insulin-dependent diabetic individual.

This case emphasizes, once again, the usefulness of performing postmortem biochemical analyses in blood or tissue samples, even in the presence of very small amounts of biological fluids or

Table 3

Case 5: Results of postmortem biochemistry analyses, which revealed increased levels of postmortem serum aldosterone and cortisol as well as increased levels of cortisol in urine.

Analyte	Blood or postmortem serum	Urine	Vitreous
Aldosterone	175 pg/ml (29–76 pg/ml)		
Cortisol	1922 nmol/l	4769 nmol/l	
ACTH	<5 pg/ml		
Sodium			158 mmol/l
Chloride			145 mmol/l
Glucose			4 mmol/l
Urea nitrogen			8 mmol/l
Creatinine			80 μmol/l
Glycated hemoglobin	6.8%		
3-β-Hydroxybutyrate	127 μmol/l		131 μmol/l

Empty boxes: parameter not evaluated.

severely decomposed bodies. These analyses should furthermore be performed in situations suggesting ketoacidosis as the possible cause of death.

5.2. Case 5

5.2.1. Primary aldosteronism presented with intracranial hemorrhage

Primary hyperaldosteronism (PA) is caused by the autonomous secretion of aldosterone from adrenocortical lesions and is associated with hypertension due to sodium retention, hypokalemia due to increased potassium excretion, and organ disorders (e.g., cerebral hemorrhage, cerebral infarction, myocardial infarction, cardiomegaly, arrhythmia, or renal insufficiency) due to inappropriate aldosterone levels [114]. PA is usually caused either by aldosterone-producing adenoma in one adrenal gland or bilateral adrenal hyperplasia of the zona glomerulosa, but it may also be caused by small hyperplastic lesions of one adrenal gland, unilateral

multiple adrenocortical nodules, bilateral aldosterone-producing adenomas, and hereditary glucocorticoid-remediable aldosteronism (also known as familial hyperaldosteronism type 1) [115–119]. Hypertension due to primary hyperaldosteronism has been recognized as a relatively benign form of hypertension

associated with a low incidence of vascular complications [120,121]. However, some reports indicate that PA complicated by cerebral vascular accidents is not infrequent [120–123]. Recent screening of hypertensive patients with simultaneous measurement of their plasma aldosterone concentration and plasma renin activity has shown that PA is the most frequent cause of second-ary hypertension [114]. An increasing number of cases of coexistent

non-malignant autonomous aldosterone and cortisol hypersecretion have been reported in the literature, most of which are associated with subclinical cortisol hyperproduction. These cases may present in different anatomical forms, including adrenocortical microadenomas or macroadenomas co-secreting cortisol and aldosterone, a combination of distinct cortisol-producing and aldosterone-producing macroadenomas, or bilateral aldosterone-producing microadenomas associated with a cortisol-producing adrenal adenoma. Irrespective of the form, hypersecretion

cortisol adds detrimental cardiovascular effects to those determined by aldosterone excesses, further enhancing cardiovascular risk [124]. We observed the case of a 48-year-old man found dead early in the morning at home in the bedroom

by the members of his family. He was not known to suffer from any particular disease, was not being treated for any condition and had not had any contact with a general practitioner in the last 4 years. When he was found dead, his body was lying face

up in bed. The macroscopic external view of the body at the death scene revealed no injuries. He was 166 cm tall and weighed 86 kg (body mass index, 31). External examination revealed the presence of multiple bruises on his upper and lower limbs, with a

maximum diameter of approximately 5 cm but no clinical features suggesting Cushing's syndrome. A CT examination carried out before the autopsy showed the presence of blood in the cerebral ventricles, a cerebral hemorrhage involving the left frontal, temporal

and parietal lobes measuring 8 cm in its maximum dimension with a right midline deviation, a cardiomegaly and the presence of a hypodense lesion of the right adrenal gland measuring approximately 4 cm in its maximum dimension. The heart weighed 550 g and showed left ventricular hypertrophy (septum and left ventricle average thickness, 2 cm). The liver weighed 2280 g and appeared yellowish brown, but no nodular lesions were found. The right adrenal gland exhibited a nodular lesion measuring 4 cm in its maximum dimension. Neuropathological examination revealed a large intraparenchymal cerebral hemorrhage in the left cerebral hemisphere associated with a rupture in the left cerebral ventricle as well as a right midline deviation, small foci of subarachnoid hemorrhage in the frontal and parietal right lobes, a subacute ischemia of the left part of the pons and a cerebral edema. Pituitary gland was normal. Histological examinations revealed a degree of myocardial hypertro-glomeruli

phy, hyalinized in the kidneys, acute visceral congestion and an adrenocortical adenoma showing a well-circumscribed tumor with a golden cut section arising from the cortex of the adrenal gland. Toxicological analyses included ethanol determination and screening for common drugs and illegal substances and

did not detect any drugs or alcohol. Biochemistry investigations were performed on postmortem serum from femoral blood (stored in tubes with no preservative), whole femoral in blood (stored tubes containing ethylenediaminetetraacetic acid), urine (stored in tubes with no preservative) and vitreous humor (stored in tubes with no preservative) and revealed increased levels of postmortem serum aldosterone and cortisol, a normal

level of blood ACTH, increased levels of urine cortisol and increased levels of vitreous sodium, chloride and glucose. Potassium determination was not carried out. The urea nitrogen and creatinine values in vitreous were within normal ranges, as were the other tested parameters. Biochemistry results are shown in Table 3.

On the basis of the autopsy, histological and biochemical results, we concluded that the cause of death was a cerebral hemorrhage, with

signs of cerebral trauma, tumor, vascular malformation or aneurism being observed. The hypothesis we supported was that of hypertension in an individual suffering from an adrenal adenoma with primary hyperaldosteronism and likely sub-hyperproduction. This

hypothesis was corroborated by the results of postmortem biochemistry investigations, revealing not only increased cortisol and aldosterone levels, but also a slight augmentation of vitreous sodium and glucose concentrations, which are biochemical features of primary hyperaldosteronism. Compared to the other cases here described, the cause

of death was evident and simple to determine, even without post-mortem biochemistry investigations.

Though biochemical results were not useful indirectly determining the cause of death, they were applicable in understanding the pathophysiological mechanisms involved in the death process,

which is also a role of the postmortem biochemistry.

Indeed, it should be asserted that forensic biochemistry can provide significant information in determining the cause of death. Moreover, these methods can also be helpful in solving forensic problems related to routine, natural deaths as well as clarifying toxicological findings.

6. Conclusions

Is postmortem biochemistry actually useful, and why is it not widely used in forensic pathology? Can we answer the questions posed by A. Lunain his article? In our opinion, perspectives with respect to postmortem biochemistry should be first updated. The aim of postmortem chemistry must not be limited to the determination of the cause of death in situations in which other analytical methods (postmortem computed tomography and

angiography, immunohistochemistry) cannot explain the death. The ability to diagnose fatal diabetic neuropathy, neuropathology, histology of ketoacidosis

must now be considered achievable in forensic pathology routine, as existing data offer sufficient evidence of the reliability of this diagnosis using vitreous glucose, glycated hemoglobin, urine glucose and blood or vitreous ketone bodies. Moreover, problems linked to the postmortem processes, artifacts that

may occur during autopsy and sample collection, analytical methods, normal ranges and result interpretation must be understood and considered by all forensic pathologists. In 2011, fatal diabetic ketoacidosis cannot be misdiagnosed.

Furthermore, postmortem biochemistry should be more widely used in many other forensic situations, most importantly to aid in interpreting the cause of death and investigating the process of death as well as contributing conditions and predisposing disorders. Additionally, it should be always born in mind that postmortem chemistry results must be interpreted very cautiously and that a single biochemical result, considered individually, is of no value without the support of other forensic results.

We are of the strong opinion that postmortem biochemical analyses must be incorporated into routine forensic investigations, which would allow this discipline to further develop its diagnostic potential and for users to create rigorous databases with sufficient numbers of cases to establish ranges of normality for forensic autopsies.

Forensic pathologists should never yield to the temptation of establishing direct links between a single biochemical result and a hypothetical cause of death. Moreover, it should never be forgotten that biochemistry is a complementary discipline that must be integrated and interpreted in the context of global findings.

We thus conclude that postmortem biochemistry can undoubtedly be useful in forensic pathology activities, that its routine use should be promoted and that it should be encouraged that these techniques be widely integrated in forensic practices.

Conflict of interest

The authors declare that they have no proprietary, financial, professional or other personal interest of any nature or kind in product, any service and or company that could be construed and influencing the position contained in the paper above presented and entitled "Usefulness of postmortem biochemistry in forensic pathology: illustrative case reports".

Acknowledgment

The authors are grateful to the anonymous reviewers whose constructive and useful comments improved the quality of this article.

References

- [1] Coe JI. Postmortem chemistry of blood, cerebrospinal fluid, and vitreous humor. In: Tedeschi CG, Eckert WC, Tedeschi LG, editors. Forensic medicine, vol. 2. Philadelphia: W.B. Saunders; 1977. p. 1030–60.
- [2] Hamilton-Paterson JL, Johnson EWM. Postmortem glycolysis. *J Pathol Bacteriol* 1940;50:473–82.
- [3] Naumann HN. Postmortem chemistry of the vitreous body in man. *Arch Ophthalmol* 1959;62:356–63.
- [4] Fekete JF, Kerényi N. Postmortem blood and blood urea nitrogen determinations. *Can Med Assoc J* 1965;92:970–3.
- [5] Finlayson NB. Blood cortisol in infants and adults: a postmortem study. *J Pediatr* 1965;67:284–92.
- [6] Leahy MS, Farber ER. Postmortem chemistry of human vitreous humor. *J Forensic Sci* 1967;12:214–22.
- [7] Coe JI. Postmortem chemistries on human vitreous humor. *Am J Clin Pathol* 1969;51:741–50.
- [8] Traub F. Methode zur Erkennung von tödlichen Zuckerstoffwechselfstörungen an der Leiche. *Zbl Allg Pathol* 1969;112:390–9.
- [9] Coe JI. Use of chemical determinations on vitreous humor in forensic pathology. *J Forensic Sci* 1972;17:541–6.
- [10] Coe JI. Some further thoughts and observations on postmortem chemistries. *Forensic Sci Gazette* 1973;5:2–6.
- [11] Coe JI. Postmortem chemistry: practical considerations and a review of the literature. *J Forensic Sci* 1974;19:13–32.
- [12] Swift PG, Worthy E, Emery JL. Biochemical state of the vitreous humor of infant necropsy. *Arch Dis Child* 1974;49:680–5.
- [13] Coe JI. Postmortem chemistry of blood, cerebrospinal fluid, and vitreous humor. *Leg Med Annu* 1977;1976:55–92.
- [14] Daae LN, Teige B, Svaar H. Determination of glucose in human vitreous humor. Various analytical methods give different results. *Z Rechtsmed* 1978;80:287–91.
- [15] Sippel H, Möttönen M. Combined glucose and lactate values in vitreous humor for postmortem diagnosis of diabetes mellitus. *Forensic Sci Int* 1982;19:217–22.
- [16] Chen C, Glagov S, Mako M, Rochman H, Rubenstein AH. Post-mortem glycosylated hemoglobin (HbA1c): evidence for a history of diabetes mellitus. *Ann Clin Lab Sci* 1983;13:407–10.
- [17] Hindle EJ, Rostron GM, Gatt J. The diagnostic value of glycated haemoglobin levels in post-mortem blood. *Ann Clin Biochem* 1985;22(Pt2):144–7.
- [18] More DS, Arroyo MC. Biochemical changes of the synovial fluid with regard to the cause of death. 1: calcium, inorganic phosphorus, glucose, urea nitrogen, uric acid, proteins, and albumin. *J Forensic Sci* 1985;30:541–6.
- [19] Kernbach G, Püschel K, Brinkmann B. Biochemical measurements of glucose in relation to cause of death and postmortem effects. *Z Rechtsmed* 1986;96:199–213.
- [20] Valenzuela A. Postmortem diagnosis of diabetes mellitus. Quantitation of fructosamine and glycated hemoglobin. *Forensic Sci Int* 1988;38:203–8.
- [21] Särkiöja T, Ylä-Herttua S, Solakivi T, Nikkari T, Hirvonen J. Stability of plasma total cholesterol, triglycerides and apolipoproteins B and A-1 during the early postmortem period. *J Forensic Sci* 1988;33:1432–8.
- [22] Coe JI. Postmortem chemistry update: emphasis on forensic application. *Am J Forensic Med Pathol* 1993;14:91–117.
- [23] Arroyo A, Valero J, Marrón T, Vidal C, Hontecillas B, Bernal J. Pericardial fluid postmortem: comparative study of natural and violent deaths. *Am J Forensic Med Pathol* 1998;19:266–8.
- [24] Madea B, Kreuzer C, Banaschak S. Postmortem biochemical examination of synovial fluid – a preliminary study. *Forensic Sci Int* 2001;118:29–35.
- [25] Arroyo A, Rosel P, Marrón T. Cerebrospinal fluid: postmortem biochemical study. *J Clin Forensic Med* 2005;12:153–6.
- [26] Madea B, Musshoff F. Postmortem chemistry. *Forensic Sci Int* 2007;165:165–71.
- [27] Uemura K, Shintani-Ishida K, Saka K, Nakajima M, Ikegaya H, Kikuchi Y, et al. Biochemical blood markers and sampling sites in forensic autopsy. *J Forensic Leg Med* 2008;15:312–7.
- [28] Thierauf A, Musshoff F, Madea B. Postmortem biochemical investigations of vitreous humor. *Forensic Sci Int* 2009;192:78–82.
- [29] Hess C, Musshoff F, Madea B. Disorders of glucose metabolism – postmortem analyses in forensic cases: part I. *Int J Legal Med* 2011;125:163–70.
- [30] Musshoff F, Hess C, Madea B. Disorders of glucose metabolism – postmortem analyses in forensic cases – part II. *Int J Legal Med* 2011;125:171–80.
- [31] Maeda H, Zhu BL, Ishikawa T, Quan L, Michiue T. Significance of postmortem in determining the cause of death. *Leg Med (Tokyo)* 2009;11:S46–9.
- [32] Maeda H, Ishikawa T, Michiue T. Forensic biochemistry for functional investigation of death: concept and practical application. *Leg Med (Tokyo)* 2011;13:55–67.

- [33] Luna A. Is postmortem chemistry really useful? Why it is not widely used in forensic pathology? *Leg Med (Tokyo)* 2009;11:S27–30.
- [34] DiMaio VJM, Sturmer WQ, Coe JI. Sudden unexpected deaths after the acute onset of diabetes mellitus. *J Forensic Sci* 1977;22:147–51.
- [35] Karlovsek MZ. Postmortem diagnosis of diabetes mellitus and diabetic coma: a comparison of HbA1c, glucose, lactate and combined glucose and lactate values in vitreous humor and in cerebrospinal fluid. In: Jacob B, Bonte W, editors. *Advances in forensic sciences: forensic criminalistic 2*, vol. 4. Berlin: Verlag Dr Köstner; 1995. p. 38–48.
- [36] Karlovsek MZ. Diagnostic values of combined glucose and lactate values in cerebrospinal fluid and vitreous humor – our experiences. *Forensic Sci Int* 2004;146:S19–23.
- [37] Osuna E, Vivero G, Conejero J, Abenza JM, Martínez P, Luna A, et al. Postmortem vitreous humor beta-hydroxybutyrate: its utility for the postmortem interpretation of diabetes mellitus. *Forensic Sci Int* 2005;153:189–95.
- [38] Kanetake J, Kanawaku Y, Mimasaka S, Sakai J, Hashiyada M, Nata M, et al. The relationship of a high level of serum beta-hydroxybutyrate to cause of death. *Leg Med (Tokyo)* 2005;7:169–74.
- [39] Felby S, Nielsen E, Thomsen JL. The postmortem distribution of ketone bodies in vitreous humor, spinal fluid and urine. *Forensic Med Pathol* 2008;4:100–7.
- [40] Zilg B, Alkass K, Berg S, Druid H. Postmortem identification of hyperglycemia. *Forensic Sci Int* 2009;185:89–95.
- [41] Irwin J, Cohle SD. Sudden death due to diabetic ketoacidosis. *Am J Forensic Med Pathol* 1988;9:119–21.
- [42] Coe JI. Sudden death due to diabetic ketoacidosis: medline search. *Am J Forensic Med Pathol* 1989;10:269–70.
- [43] Yamazaki M, Ogura Y, Wakasugi C, Mitsukuni Y, Yoshimura M. Sudden death due to diabetic coma in insulin-dependent diabetes mellitus: an autopsy report. *Nihon Hoigaku Zasshi* 1997;51:102–10.
- [44] Rozin L, Perper JA, Jabbe R, Drash A. Sudden unexpected death in childhood due to unsuspected diabetes mellitus. *Am J Forensic Med Pathol* 1994;15:251–6.
- [45] Sturmer WQ. Short and sweet: looking for sugar. *Am J Forensic Med Pathol* 1995;16:261.
- [46] Avella J, Wetli CV, Wilson JC, Katz M, Hahn T. Fatal olanzapine-induced hyperglycemic ketoacidosis. *Am J Forensic Med Pathol* 2004;25:172–5.
- [47] Byard RW, Riches KJ, Kostakis C, Felgate HE. Diabetic ketoacidosis – possible factor in deaths associated with drug overdoses. *Forensic Med Pathol* 2006;46:81–4.
- [48] House CJ. Olanzapine-induced hyperglycemic ketoacidosis and corresponding acetone concentrations post-mortem: a forensic interpretation. *Forensic Sci Int* 2007;171:22–6.
- [49] Kashiwagi M, Hara K, Liu Z, Kageura M, Matsusue A, Sugimura T, et al. Diagnostic approach to drug-screening tests for fatal diabetic ketoacidosis: forensic autopsy of a methamphetamine abuser. *Leg Med (Tokyo)* 2010;12:192–4.
- [50] Madea B, Lachenmeier DW. Postmortem diagnosis of hypertonic dehydration. *Forensic Sci Int* 2005;155:1–6.
- [51] Druid H, Holmgren P, Carlsson B, Ahlner J. Cytochrome P450 2D6 (CYP2D6) genotyping on postmortem blood as a supplementary tool for interpretation of forensic toxicological results. *Forensic Sci Int* 1999;99:25–34.
- [52] Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and pharmacology, genetics, biochemistry. *Naunyn-Schmiedeberg Arch Pharmacol* 2004;369:23–37.
- [53] Jannetto PJ, Laleli-Sahin E, Wong SH. Pharmacogenomic genotyping methodologies. *Clin Chem Lab Med* 2004;42:1256–64.
- [54] Zackrisson AL, Holmgren P, Gladh AB, Ahlner J, Lindblom B. Fatal intoxication cases: cytochrome P450 2D6 and 2C19 genotype distribution. *Eur J Clin Pharmacol* 2004;60:547–52.
- [55] Kopic TC, Rajiv V, Vu N. Pharmacogenomics for the forensic toxicologist. *J Anal Toxicol* 2006;30:65–72.
- [56] Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for cytochrome P450 2D6 phenotyping. *Eur J Clin Pharmacol* 2007;63:321–33.
- [57] Neafsey P, Ginsberg G, Hattis D, Sonawane B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. *J Toxicol Environ Health B Crit Rev* 2009;12:334–61. [58]
- Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. *Clin Pharmacokinet* 2009;48:689–723.
- [59] Jannetto PJ, Wong SH, Gogk SB, Laleli-Sahin E, Schur BC, Jentzen JM. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. *J Anal Toxicol* 2002;26:438–47.
- [60] Levo A, Koski A, Ojanperä I, Vuori E, Sajantila A. Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood. *Forensic Sci Int* 2003;135(1):9–15.
- [61] Wong SH, Wagner MA, Jentzen JM, Schur C, Bjerke J, Gock SB, et al. Pharmacogenomics as an aspect of molecular autopsy for forensic pathology/toxicology: does genotyping CYP 2D6 serve as an adjunct for certifying methadone toxicity? *J Forensic Sci* 2003;48(6):1406–15.
- [62] Jin M, Gock SB, Jannetto PJ, Jentzen JM, Wong SH. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. *J Anal Toxicol* 2005;29(7):590–8.
- [63] Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S. Interindividual variability of methadone response: impact of genetic polymorphism. *Mol Diagn Ther* 2008;12:109–24.
- [64] Ferreiros N, Dresen S, Hermanns-Clausen M, Auwaerter V, Thierauf A, Müllerer C, et al. Fatal and severe codeine intoxication in a 3-year-old twins – interpretation of drug and metabolite concentrations. *Int J Legal Med* 2009;123:387–94.
- [65] Sallee FR, DeVane CL, Ferrell RE. Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. *J Child Adolesc Psychopharmacol* 2000;10:27–34.
- [66] Charlier C, Broly F, Lhermitte M, Pinto E, Anseau M, Plomteux G. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. *Ther Drug Monit* 2003;25(6):738–42.
- [67] Holmgren P, Carlsson B, Zackrisson AL, Lindblom B, Dahl ML, Scordo MG, et al. Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19. *J Anal Toxicol* 2004;28(2):94–104.
- [68] Koski A, Sistonen J, Ojanperä I, Gergov M, Vuori E, Sajantila A. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. *Forensic Sci Int* 2006;158(2-3):177–83.
- [69] Koski A, Ojanperä I, Sistonen J, Vuori E, Sajantila A. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. *Am J Forensic Med Pathol* 2007;28(3):259–61.
- [70] Maier W, Zobel A. Contribution of allelic variations to the phenotype of response to antidepressant and antipsychotics. *Eur Arch Psychiatry Clin Neurosci* 2008;258(Suppl 1):12–20.
- [71] Mörike K, Magadam S, Mettang T, Griesse EU, Machleidt C, Kuhlmann U. Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy. *J Internal Med* 1995;238:469–742.
- [72] Jazwinska-Tarnawska E, Orzechowska-Juzwenko K, Niewinski P, Rzemislawska Z, Loboż-Grudzien K, Dmochowska-Perz M, et al. The influence of CYP2D6 polymorphism on the antiarrhythmic efficacy of propafenone in patients with paroxysmal atrial fibrillation during 3 months propafenone prophylactic treatment. *Int J Clin Pharmacol Ther* 2001;39:288–92.
- [73] Martínez-Sellés M, Castilló, Montenegro P, Martín ML, Almendra J, Sanjurjo M. Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation. *Rev Esp Cardiol* 2005;58:645–8.
- [74] Doki K, Homma M, Kuga K, Kusano K, Watanabe S, Yamaguchi I, et al. Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. *Eur J Clin Pharmacol* 2006;62:919–26. [75] Doki K, Homma M, Kuga K, Aonuma K, Sakai S, Yamaguchi I, et al. Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia. *Eur J Clin Pharmacol* 2007;63(10):951–7.
- [76] Bijl MJ, Visser LE, van Schaik RHN, Kors JA, Wittman JCM, Hofman A, et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate blood pressure in beta-blocker users. *Clin Pharmacol Ther* 2009;85:45–50.
- [77] Doki K, Homma M, Kuga K, Aonuma K, Kohda Y. Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. *Br J Clin Pharmacol* 2009;68(1):89–96.
- [78] Ovaska H, Ludman A, Spencer EP, Wood DM, Jones AL, Dargan PI. Propafenone poisoning: a case report with plasma propafenone concentrations. *J Med Toxicol* 2010;6:37–40.
- [79] Lim KS, Jang IJ, Kim BH, Kim J, Jeon JY, Tae YM, et al. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects. *Clin Ther* 2010;32(4):659–66. [80]
- Levine B, Chute D, Caplan YH. Flecainide intoxication. *J Anal Toxicol* 1990;14(5):335–6.
- [81] Forrest AR, Marsh J, Galloway JH, Gray PB. A rapidly fatal overdose with flecainide. *J Anal Toxicol* 1991;15(1):41–3.
- [82] Rogers C, Anderson DT, Ribe JK, Sathyavagiswaran L. Fatal flecainide intoxication. *J Anal Toxicol* 1993;17(7):434–5.
- [83] Sadler DW, Quigley C. Unsuspected self-poisoning with flecainide and alcohol. *J Forensic Sci* 1995;40(5):903–5.
- [84] Brazil E, Bodiwala GG, Bouch DC. Fatal flecainide intoxication. *J Accid Emerg Med* 1998;15(6):423–5.
- [85] Maury P, Vuille C, Metzger J, Veragut B, Schoenenberger I, Emlamly A, et al. Severe flecainide acetate poisoning. A propos of a case. *Arch Mal Coeur Vaiss* 1999;92:273–7.
- [86] Romain N, Giroud C, Michaud K, Augsburger M, Mangin P. Fatal flecainide intoxication. *Forensic Sci Int* 1999;106:115–23.
- [87] Lynch MJ, Gerostamoulos J. Flecainide toxicity: cause and contribution to death. *Legal Medicine* 2001;3:233–6.
- [88] Benijts T, Borrey D, Lambert WE, De Letter EA, Piette MH, Van Peteghem C, et al. Analysis of flecainide and two metabolites in biological specimens by HPLC: application to a fatal intoxication. *J Anal Toxicol* 2003;27(1):47–52. [89] Airaksinen KE, Koistinen MJ. ECG findings in fatal flecainide intoxication. *Heart* 2007;93(12):1499.
- [90] D'Alessandro LC, Rieder MJ, Gloor J, Freeman D, Buffo-Sequiera I. Life-threatening flecainide intoxication in a young child secondary to medication error. *Ann Pharmacother* 2009;43(9):1522–7.

- [91] Doniz Campos M, Illodo Miramontes G, Bobillo B, Otero Amoedo T, Filgueira P, López Rey F, et al. Flecainide poisoning. *Rev Esp Anestesiología Reanim* 2010;57:596–8.
- [92] Braun J, Kollert JR, Becker JU. Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function. *Eur J Clin Pharmacol* 1987;31:711–4.
- [93] Forland SC, Burgess E, Blair AD, Cutler RE, Kvam DC, Weeks CE, et al. Oral flecainide pharmacokinetics in patients with impaired renal function. *J Clin Pharmacol* 1988;28:259–67.
- [94] Williams AJ, McQuinn RL, Walls J. Pharmacokinetics of flecainide acetate in patients with severe renal impairment. *Clin Pharmacol Ther* 1988;43:449–55.
- [95] Mikus G, Gross AS, Beckmann J, Hertrampf HR, Gundert-Remy U, Eichelbaum M. The influence of the spartein/debrisoquine phenotype on the disposition of flecainide. *Clin Pharmacol Ther* 1989;45:562–7.
- [96] Evers J, Eichelbaum M, Kroemer HK. Unpredictability flecainide plasma concentrations in patients with renal failure: relationship to side effects and sudden death? *Ther Drug Monit* 1994;16:349–51.
- [97] Tennezé L, Tarral E, Ducloux N, Funck-Brentano C. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. *Clin Pharmacol Ther* 2002;72:112–22.
- [98] Hirvonen J. Necropsy findings in fatal hypothermia cases. *Forensic Sci Int* 1976;8:155–64.
- [99] Hirvonen J, Huttunen P. Increased urinary concentration of catecholamines in hypothermia deaths. *J Forensic Sci* 1982;27:264–71.
- [100] Bray M, Luke JL, Blackburne BD. Vitreous humor chemistry in deaths associated with rapid chilling and prolonged freshwater immersion. *J Forensic Sci* 1983;28:588–93.
- [101] Coe JI. Hypothermia: autopsy findings and vitreous glucose. *J Forensic Sci* 1984;29:389–95.
- [102] Ishikawa T, Miyaiishi S, Tachibana T, Ishizu H, Zhu BL, Maeda H. Fatal hypothermia related vacuolation of hormone-producing cells in the anterior pituitary. *Leg Med (Tokyo)* 2004;6:157–63.
- [103] Ishikawa T, Quan L, Li DR, Zhao D, Michiue T, Hamel M, et al. Postmortem biochemistry and immunohistochemistry of adrenocorticotrophic hormone with special regard to fatal hypothermia. *Forensic Sci Int* 2008;179:147–51.
- [104] Ishikawa T, Michiue T, Zhao D, Komatsu A, Azuma Y, Quan L, et al. Evaluation of postmortem serum and cerebrospinal fluid levels of thyroid-stimulating hormone with special regard to fatal hypothermia. *Leg Med (Tokyo)* 2009;11 Suppl 1:S228–30.
- [105] Ishikawa T, Yoshida C, Michiue T, Perdekamp MG, Pollak S, Maeda H. Immunohistochemistry of catecholamine in the hypothalamic-pituitary-adrenal system with special regard to fatal hypothermia and hyperthermia. *Leg Med (Tokyo)* 2010;12:121–7.
- [106] Yoshida C, Ishikawa T, Michiue T, Quan L, Maeda H. Postmortem biochemistry and immunohistochemistry of chromogranin A as a stress marker with special regard to fatal hypothermia and hyperthermia. *Int J Legal Med* 2011;125:11–20.
- [107] Quan L, Ishikawa T, Hara J, Michiue T, Chen JH, Wang Q, et al. Postmortem serotonin levels in cerebrospinal and pericardial fluids with regard to the cause of death in medicolegal autopsy. *Leg Med (Tokyo)* 2011;13:75–8.
- [108] Teresin'ski G, Buszewicz G, Ma dro R. The influence of ethanol on the level of ketone bodies in hypothermia. *Forensic Sci Int* 2002;127(1–2):88–96.
- [109] Teresin'ski G, Buszewicz G, Ma dro R. Biochemical background of ethanol-induced cold susceptibility. *Leg Med (Tokyo)* 2005;7(1):15–23.
- [110] Teresin'ski G, Buszewicz G, Ma dro R. Acetonemia as an initial criterion of evaluation of a probable cause of sudden death. *Leg Med (Tokyo)* 2009;11(1):18–24.
- [111] Smialek JE, Levine B. Diabetes and decomposition: a case of diabetic ketoacidosis with advanced postmortem changes. *Am J Forensic Med Pathol* 1998;19:98–101.
- [112] Statheropoulos M, Spiliopoulou C, Agapiou A. A study of volatile organic compounds evolved from the decaying human body. *Forensic Sci Int* 2005;153:147–55.
- [113] Statheropoulos M, Agapiou A, Spiliopoulou C, Pallis GC, Sianos E. Environmental aspects of VOCs evolved in the early stages of human decomposition. *Sci Total Environ* 2007;385:221–7.
- [114] Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, et al. Guidelines for the diagnosis and treatment of primary aldosteronism. The Japan Endocrine Society 2009. doi:10.1507/endocrj.EJ11-013.
- [115] Fuse H, Mizuno I, Nagakawa O, Kazama T, Terada T, Katayama T, et al. A case of primary aldosteronism due to unilateral multiple adrenal adenomas. *Hinyokika Kyo* 1990;36:819–22.
- [116] Hirono Y, Doi M, Yoshimoto T, Kanno K, Himeno Y, Taki K, et al. A case with primary aldosteronism due to unilateral multiple adrenocortical micronodules. *Endocr J* 2005;52:435–9.
- [117] Leung AM, Sasano H, Nishikawa T, McAneny DB, Malabanan AO. Multiple unilateral adrenal adenomas in a patient with primary hyperaldosteronism. *Endocr Pract* 2008;14:76–9.
- [118] Myint KS, Watts M, Appleton DS, Lomas DJ, Jamieson N, Taylor KP, et al. Primary hyperaldosteronism due to adrenal microadenoma: a curable cause of refractory hypertension. *Angiotensin Aldosterone Syst* 2008;9:103–6.
- [119] Hashimoto N, Kawamura Y, Nakamura T, Murawaki A, Nishiumi T, Hirota Y, et al. A case of primary aldosteronism caused by multiple adrenocortical macronodules. *Intern Med* 2011;50:585–90.
- [120] Nakagawa A, Su CC, Saito K, Yamashita Y, Shirane Y, Yoshimoto T, et al. Primary aldosteronism presented with intracranial hemorrhage. *No Shinkei Geka* 2001;29:973–7.
- [121] Sawada K, Maehara T, Inaji M, Toriyama H, Okada T, Nariai T, et al. Case of ruptured multiple cerebral aneurysms associated with primary aldosteronism. *No Shinkei Geka* 2010;38:347–51.
- [122] Hausser CO, Ouaknine GE, Primeau F, Kuchel O. Multiple intracranial aneurysms associated with primary hyperaldosteronism. *Rev Neurol (Paris)* 1985;141:46–8.
- [123] Hiraiwa T, Iбата R, Tanimoto K, Yamamoto N, Terasaki J, Azuma H, et al. Acute cerebral hemorrhage normalized plasma rennin activity in a patient with primary aldosteronism. *Endocrine* 2009;36:383–4.
- [124] Fallo F, Bertello C, Tizzani D, Fassina A, Boulkroun S, Sonino N, et al. Concurrent primary aldosteronism and subclinical cortisol hypersecretion: a prospective study. *J Hypertens* 2011;29:1773–7.